The Botswana Medicines Regulatory Authority (BOMRA) wishes to bring to your attention a safety concern associated with the use of Proton Pump Inhibitors (PPIs), specifically their potential to trigger acute interstitial nephritis, a serious adverse event linked to acute kidney injury.